Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» The ‘don’t eat me’ antidote: GlaxoSmithKline, Roche and Novo back $86M startup in high-stakes CD47 showdown
The ‘don’t eat me’ antidote: GlaxoSmithKline, Roche and Novo back $86M startup in high-stakes CD47 showdown
The ‘don’t eat me’ antidote: GlaxoSmithKline, Roche and Novo back $86M startup in high-stakes CD47 showdown
Submitted by
admin
on August 16, 2016 - 11:16am
Source:
Endpoints
News Tags:
GSK
Roche
Novo Nordisk
Tioma Therapeutics
CD47
immuno-oncology
Headline:
The ‘don’t eat me’ antidote: GlaxoSmithKline, Roche and Novo back $86M startup in high-stakes CD47 showdown
Do Not Allow Advertisers to Use My Personal information
